Phasebio Pharmaceuticals Stock Fundamentals
| PHASQDelisted Stock | USD 0.0003 0.0001 25.00% |
PhaseBio Pharmaceuticals fundamentals help investors to digest information that contributes to PhaseBio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of PhaseBio Pink Sheet. The fundamental analysis module provides a way to measure PhaseBio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PhaseBio Pharmaceuticals pink sheet.
PhaseBio |
PhaseBio Pharmaceuticals Company Return On Asset Analysis
PhaseBio Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current PhaseBio Pharmaceuticals Return On Asset | -1.06 |
Most of PhaseBio Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PhaseBio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, PhaseBio Pharmaceuticals has a Return On Asset of -1.0607. This is 87.88% lower than that of the Healthcare sector and 95.51% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
PhaseBio Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PhaseBio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare PhaseBio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PhaseBio Pharmaceuticals competition to find correlations between indicators driving PhaseBio Pharmaceuticals's intrinsic value. More Info.PhaseBio Pharmaceuticals is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PhaseBio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.PhaseBio Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PhaseBio Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PhaseBio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing PhaseBio Pharmaceuticals by comparing valuation metrics of similar companies.PhaseBio Pharmaceuticals is currently under evaluation in return on asset category among its peers.
PhaseBio Fundamentals
| Return On Asset | -1.06 | |||
| Operating Margin | (127.39) % | |||
| Current Valuation | (1.26 M) | |||
| Shares Outstanding | 49.86 M | |||
| Shares Owned By Insiders | 6.72 % | |||
| Shares Owned By Institutions | 25.02 % | |||
| Number Of Shares Shorted | 2.07 M | |||
| Price To Book | 26.18 X | |||
| Price To Sales | 1.58 X | |||
| Revenue | 10.83 M | |||
| Gross Profit | (91.28 M) | |||
| EBITDA | (126.73 M) | |||
| Net Income | (131.07 M) | |||
| Cash And Equivalents | 7.8 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.36 M | |||
| Current Ratio | 0.47 X | |||
| Book Value Per Share | (2.35) X | |||
| Cash Flow From Operations | (47.42 M) | |||
| Short Ratio | 1.89 X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 60 | |||
| Beta | 2.52 | |||
| Market Capitalization | 1.05 M | |||
| Total Asset | 60.54 M | |||
| Z Score | -6.6 | |||
| Net Asset | 60.54 M |
About PhaseBio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PhaseBio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PhaseBio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PhaseBio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Phasebio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 60 people.
Pair Trading with PhaseBio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PhaseBio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to PhaseBio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PhaseBio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PhaseBio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PhaseBio Pharmaceuticals to buy it.
The correlation of PhaseBio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PhaseBio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PhaseBio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PhaseBio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |